© Bestenbalt
Bestenbalt news
Tallinn, December, 2006. Bestenbalt LLC signed a three-year collaboration agreement with University of Tasmania, Australia. The collaboration involves identification of specific structural features of metallothionein that regulate its ability to modulate astrogliosis.
Project Title: Identifying the specific structural features of
metallothionein that regulate its ability to modulate astrogliosis
Collaborating/Partner Organisation(s): University of
Tasmania, Australia; Bestenbalt LLC, Tallinn, Estonia.
Project Summary:
This project contributes directly to the Designated National Research Priority 2
and could potentially have a significant impact upon the broader Australian
Community by identifying a novel and powerful therapeutic agent based upon
metallothionein proteins with the ultimate aim of helping patients who have a
brain injury or a neurodegenerative disease. It is important to note that the
partnership between UTAS and Bestenbalt LLC is a critical step in the
development of these exciting research discoveries into commercially viable
outcomes for the Australian Biotechnology Industry and the broader Australian
community. (Source: ARC, Australian Research Council).
© Bestenbalt LLC, 2002-2010